 Connection
M Cave to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications M Cave has written about Tuberculosis, Multidrug-Resistant.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.385 |
|
|
|
-
Yang ZH, Rendon A, Flores A, Medina R, Ijaz K, Llaca J, Eisenach KD, Bates JH, Villarreal A, Cave MD. A clinic-based molecular epidemiologic study of tuberculosis in Monterrey, Mexico. Int J Tuberc Lung Dis. 2001 Apr; 5(4):313-20.
Score: 0.187
-
Hazb?n MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garc?a-Garc?a L, Le?n CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Le?n A, Alland D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006 Aug; 50(8):2640-9.
Score: 0.068
-
Ramaswamy SV, Dou SJ, Rendon A, Yang Z, Cave MD, Graviss EA. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol. 2004 Feb; 53(Pt 2):107-113.
Score: 0.057
-
Wilson RW, Yang Z, Kelley M, Cave MD, Pogoda JM, Wallace RJ, Cegielski JP, Dunbar DF, Bergmire-Sweat D, Elliott LB, Barnes PF. Evidence from molecular fingerprinting of limited spread of drug-resistant tuberculosis in Texas. J Clin Microbiol. 1999 Oct; 37(10):3255-9.
Score: 0.042
-
Nolan CM, Williams DL, Cave MD, Eisenach KD, el-Hajj H, Hooton TM, Thompson RL, Goldberg SV. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med. 1995 Sep; 152(3):1067-71.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|